Coherus BioSciences (CHRS) News Today $1.12 +0.11 (+10.89%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.09 -0.03 (-2.68%) As of 04/17/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Coherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Coherus BioSciences from a "hold" rating to a "sell" rating in a report on Tuesday.April 17 at 11:12 PM | marketbeat.comCoherus BioSciences: Cleaning The Balance Sheet And Developing New DrugsApril 17 at 6:00 AM | seekingalpha.comCoherus BioSciences (NASDAQ:CHRS) Downgraded by StockNews.com to "Sell"April 17 at 1:26 AM | americanbankingnews.comCoherus Biosciences completes divestiture of UDENYCA franchiseApril 15 at 12:07 AM | markets.businessinsider.comCoherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® FranchiseApril 14, 2025 | globenewswire.comCoherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated NotesApril 3, 2025 | nasdaq.comCoherus Biosciences announces repurchase of $170M of convertible notesApril 1, 2025 | markets.businessinsider.comCoherus Announces Repurchase of Approximately $170 Million of Convertible NotesApril 1, 2025 | markets.businessinsider.comLobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosedMarch 26, 2025 | nasdaq.comCoherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comStatutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True PositionMarch 24, 2025 | finance.yahoo.comA Closer Look At Coherus BioSciences' EarningsMarch 24, 2025 | uk.finance.yahoo.comCoherus BioSciences Full Year 2024 Earnings: Beats ExpectationsMarch 14, 2025 | finance.yahoo.comCoherus BioSciences, Inc. (CHRS): A Bull Case TheoryMarch 12, 2025 | insidermonkey.comCoherus BioSciences (NASDAQ:CHRS) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Coherus BioSciences in a report on Tuesday.March 12, 2025 | marketbeat.comQ4 2024 Coherus BioSciences Inc Earnings CallMarch 11, 2025 | uk.finance.yahoo.comTruist Financial Sticks to Their Buy Rating for Coherus Biosciences (CHRS)March 11, 2025 | markets.businessinsider.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | msn.comCoherus BioSciences (NASDAQ:CHRS) Posts Earnings Results, Misses Expectations By $0.34 EPSCoherus BioSciences (NASDAQ:CHRS - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.34).March 11, 2025 | marketbeat.comCoherus Biosciences to reduce headcount by 30%March 10, 2025 | markets.businessinsider.comCoherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comCoherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business UpdateMarch 10, 2025 | globenewswire.comCoherus BioSciences (CHRS) Expected to Announce Earnings on MondayCoherus BioSciences (NASDAQ:CHRS) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=672012)March 5, 2025 | marketbeat.comCoherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025March 3, 2025 | globenewswire.comWith 59% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big gunsFebruary 27, 2025 | finance.yahoo.comCoherus Management to Participate at the 45th Annual TD Cowen Health Care ConferenceFebruary 24, 2025 | globenewswire.comCoherus BioSciences, Inc. (CHRS): A Bull Case TheoryFebruary 12, 2025 | msn.comCoherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyCoherus BioSciences (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving Average - Should You Sell?January 31, 2025 | marketbeat.comCoherus Biosciences: Promising Phase 2 Data and Strategic Valuation Drive Buy RatingJanuary 24, 2025 | markets.businessinsider.comCoherus BioSciences's SWOT analysis: stock faces headwinds amid oncology pivotJanuary 24, 2025 | msn.comCoherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Coherus BioSciences in a research note on Thursday.January 23, 2025 | marketbeat.comCoherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025January 22, 2025 | finance.yahoo.comCoherus Reports Final Phase 2 Casdozokitug Combination Data In Hepatocellular CarcinomaJanuary 22, 2025 | markets.businessinsider.comCoherus Biosciences presents final Phase 2 clinical casdozokitug dataJanuary 22, 2025 | markets.businessinsider.comCoherus Management to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | finance.yahoo.comCoherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Here's WhyCoherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - What's Next?January 8, 2025 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedCoherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?December 31, 2024 | marketbeat.comCoherus Biosciences to present final Phase 2 casdozokitug combination dataDecember 18, 2024 | markets.businessinsider.comCoherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025December 18, 2024 | globenewswire.comCoherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing DevelopmentDecember 16, 2024 | seekingalpha.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Sees Large Drop in Short InterestCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 30,720,000 shares, a decline of 7.0% from the November 15th total of 33,040,000 shares. Based on an average daily trading volume, of 5,120,000 shares, the days-to-cover ratio is currently 6.0 days.December 16, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $262,000 Stock Holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS)Jacobs Levy Equity Management Inc. cut its position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 74.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 252,330 shares of the biotechnology compDecember 11, 2024 | marketbeat.comDisciplined Growth Investors Inc. MN Trims Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)Disciplined Growth Investors Inc. MN decreased its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 39.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 766,308 shares of the biotechnology company's stock aftDecember 10, 2024 | marketbeat.comCoherus BioSciences, Inc. Common Stock (CHRS)December 9, 2024 | nasdaq.comRedwood City-based Coherus' stock surges after major drug saleDecember 4, 2024 | bizjournals.comCoherus Biosciences Sells UDENYCA Franchise to IntasDecember 4, 2024 | markets.businessinsider.comCoherus Biosciences agrees to divest UDENYCA franchise for up to $558MDecember 4, 2024 | markets.businessinsider.comRaleigh pharmaceutical company expands portfolio with $558M dealDecember 3, 2024 | bizjournals.comCalifornia-Based Biotech Rallies Strongly Following $558.4M DivestitureDecember 3, 2024 | theglobeandmail.comWhy Is Coherus BioSciences Stock Trading Higher On Tuesday?December 3, 2024 | benzinga.com Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Media Mentions By Week CHRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRS News Sentiment▼0.230.49▲Average Medical News Sentiment CHRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRS Articles This Week▼52▲CHRS Articles Average Week Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maravai LifeSciences News Tyra Biosciences News SIGA Technologies News Relay Therapeutics News Akebia Therapeutics News MeiraGTx News Mind Medicine (MindMed) News Precigen News Stoke Therapeutics News Sana Biotechnology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHRS) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRS Stock Free CHRS Stock Alerts